Bliuc D, Tran T, van Geel T, et al. - Researchers conducted this mediation analysis to ascertain if the reduction in the rate of bone loss mediates the relationship between bisphosphonates and mortality through prospectively following participants from the population-based Canadian Multicentre Osteoporosis Study between 1996 and 2011. Using linear regression, the rate of bone loss was calculated, and annual information was acquired on the use of medication. Compared with no loss, rapid bone loss was related to a more than twofold higher mortality risk. According to findings, 39% of the nitrogen bisphosphonates (nBP; alendronate or risedronate) association with mortality was related to a decline in the rate of bone loss. This finding offers an insight into the mechanism of the connection in osteoporotic patients between nBP and survival benefit.